Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.

American journal of kidney diseases : the official journal of the National Kidney Foundation - 1 Jul 1995

Brown C D, Azrolan N, Thomas L, Roberts K G, Bostom A, Zhao Z H, Friedman E A

Abstract excerpt

Pharmocologic treatment of the hyperlipidemia associated with the nephrotic syndrome with lovastatin has been previously shown to be safe and effective. However, there is no information on the effect of lovastatin treatment on plasma lipoprotein(a) [Lp(a)] levels in patients with the nephrotic syndrome. We administered lovastatin (40 to 80 mg/day) to 20 adult patients with unremitting nephrotic syndrome for 8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Apolipoproteins A

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cholesterol

Share to Cholesterol, LDL

Share to Lipoprotein(a)

Share to Lovastatin

Share to Nephrotic Syndrome

Share to Phenotype

Source

Identifiers

PMID: 7611249
DOI: 10.1016/0272-6386(95)90171-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome.PMID 7611249Read ↗

Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome.Semantic proximity Read ↗

The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome.Semantic proximity Read ↗

Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.Semantic proximity Read ↗

Changes in serum lipoprotein(a) levels in children with corticosensitive nephrotic syndrome.Semantic proximity Read ↗

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.Semantic proximity Read ↗

The atherogenic lipoprotein phenotype in renal diseaseSemantic proximity Read ↗

Is dyslipidemia sustained during remission of nephrotic syndrome genetically determined? Evaluation of genetic polymorphisms of proteins involved in lipoprotein metabolism in children and adolescents with nephrotic syndrome.Semantic proximity Read ↗

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation.Semantic proximity Read ↗

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).Semantic proximity Read ↗

Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.Semantic proximity Read ↗

Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.Semantic proximity Read ↗

Lipoprotein apheresis as rescue therapy in lipoprotein glomerulopathy: The role of plasmatic extracellular vesicle removal.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.